Algert Global LLC Lowers Stock Position in TG Therapeutics, Inc. $TGTX

Algert Global LLC decreased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 38.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 62,121 shares of the biopharmaceutical company's stock after selling 39,360 shares during the quarter. Algert Global LLC's holdings in TG Therapeutics were worth $3,413,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its stake in TG Therapeutics by 51.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 365 shares in the last quarter. Maryland State Retirement & Pension System grew its holdings in shares of TG Therapeutics by 2.0% during the 4th quarter. Maryland State Retirement & Pension System now owns 19,899 shares of the biopharmaceutical company's stock worth $593,000 after purchasing an additional 393 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of TG Therapeutics by 1.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company's stock worth $1,135,000 after purchasing an additional 441 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in TG Therapeutics by 16.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 3,147 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 454 shares in the last quarter. Finally, HB Wealth Management LLC increased its stake in shares of TG Therapeutics by 6.7% in the first quarter. HB Wealth Management LLC now owns 7,514 shares of the biopharmaceutical company's stock worth $250,000 after buying an additional 475 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Zacks Research upgraded shares of TG Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday, June 1st. Jefferies Financial Group reaffirmed a "buy" rating and set a $83.00 target price on shares of TG Therapeutics in a research report on Monday, June 22nd. HC Wainwright reissued a "buy" rating and issued a $78.00 price target on shares of TG Therapeutics in a research report on Tuesday, August 4th. JPMorgan Chase & Co. raised their price objective on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Finally, Bank of America lifted their target price on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an "underperform" rating in a report on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, TG Therapeutics currently has a consensus rating of "Hold" and an average target price of $63.00.

TG Therapeutics Stock Down 3.2%

Shares of NASDAQ TGTX opened at $53.93 on Friday. TG Therapeutics, Inc. has a 12 month low of $26.76 and a 12 month high of $59.30. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. The company has a market cap of $8.26 billion, a price-to-earnings ratio of 19.68, a PEG ratio of 2.39 and a beta of 1.62. The stock has a 50-day moving average price of $53.37 and a two-hundred day moving average price of $41.82.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.26). The business had revenue of $240.34 million during the quarter, compared to analyst estimates of $229.77 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The company's revenue was up 70.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.17 earnings per share. As a group, analysts forecast that TG Therapeutics, Inc. will post 0.92 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source